Herceptin

HER2 targeted therapies have substantially improved the prognosis of patients with breast cancer however they can be associated with cardiac...


Investigational hunter immune cells engineered to seek out and attack a deadly brain cancer known as glioblastoma ( GBM )...


Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in...


Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs...


Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy...


PIK3CA mutations are common in breast cancer. The aim of a study was to evaluate the correlation of PIK3CA mutational...


The CHER-LOB randomized phase II study showed that the combination of Lapatinib ( Tyverb ) and Trastuzumab ( Herceptin )...


Results from the phase III clinical trial of the investigational drug PB272 ( Neratinib ) for the extended adjuvant treatment...


In the randomised, controlled, phase 3 trial NeOAdjuvant Herceptin ( NOAH ) trial in women with HER2-positive locally advanced or...


Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the...


A new breast cancer vaccine candidate, ( GP2 ), provides further evidence of the potential of immunotherapy in preventing disease...


GP2 is a HER2 derived, HLA-A2+-restricted immunogenic peptide designed to stimulate CD8+T cells to recognize tumor cells with any level...


Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the...


Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 ( known...


Data from a pooled analysis presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (...


Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the...


Roche has announced that Kadcyla ( Trastuzumab emtansine or T-DM1 ) has been approved by the European Commission for people...


The College of American Pathologists ( CAP ) and the American Society of Clinical Oncology ( ASCO ) have issued...


New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to...